Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Articles about Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Is Puma Biotechnology a Buy? | The Motley Fool
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Puma Biotechnology - Crunchbase Company Profile & Funding
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
PumaBiotech (@pumabiotech) / Twitter
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Puma Biotechnology, Inc. | LinkedIn
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
